Glaxo executive opposes splitting FDA reviews

GlaxoSmithKline's R&D chairman opposes creation of a separate agency to monitor the safety of FDA-approved drugs. Tachi Yamada said splitting the process is a hazardous idea and drugs should be reviewed in their totality. Separately, a Journal and Constitution editorial supports the proposal to create an agency independent of the FDA because the agency no longer has the trust of the public.

View Full Article in:

Reuters · Journal and Constitution (Atlanta) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ